Pfizer Inc
Change company Symbol lookup
Select an option...
PFE Pfizer Inc
XEL Xcel Energy Inc
GE General Electric Co
ADP Automatic Data Processing Inc
CNTB Connect Biopharma Holdings Ltd
SLV iShares Silver Trust
OFSI Omni Financial Services Inc
APA APA Corp (US)
HBI HanesBrands Inc
SHWDY Resonac Holdings Corp
Go

Health Care : Pharmaceuticals | Large Cap Value
Company profile

Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operations through two segments: Biopharma and PC1. Biopharma is a science-based medicines business that includes six therapeutic areas, such as Vaccines, Hospital, Oncology, Internal Medicine, Rare Disease, and Inflammation & Immunology. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. Its Vaccines include Comirnaty/BNT162b2, the Prevnar family, Nimenrix and others. Its Oncology products include Ibrance, Xtandi, Inlyta, Sutent, Retacrit, Lorbrena and Braftovi. Its Internal Medicine products include Eliquis and the Premarin family. Its Inflammation & Immunology products include Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis and Cibinqo. It also offers Rimegepant and Zavegepant.

Postmarket

Last Trade
Delayed
$44.29
-0.05 (-0.11%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$44.34
Day's Change
0.37 (0.84%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Heavy Day)
Volume:
35,273,129

10-day average volume:
27,902,889
35,273,129

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfizer Inc. - PFE

2:35 pm ET November 14, 2022 (PR Newswire) Print

Pomerantz LLP is investigating claims on behalf of investors ofPfizer Inc.("Pfizer" or the "Company")(NYSE:PFE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.comor 888-476-6529, ext. 7980.

https://mma.prnewswire.com/media/1486339/Pomerantz_Logo.jpg

The investigation concerns whether Pfizer and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On October 26, 2022, Bloomberg reported that Italian authorities are investigating Pfizer for allegedly hiding profits of at least EUR1.2 billion by transferring money to business units in other countries, including the U.S. and the Netherlands, to avoid taxes. The probe began in February and covers 2017 through 2019.

On this news, Pfizer's stock price fell $0.32 per share, or 0.69%, to close at $45.74 per share on October 27, 2022.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

CONTACT:Robert S. WilloughbyPomerantz LLPrswilloughby@pomlaw.com888-476-6529 ext. 7980

https://c212.net/c/img/favicon.png?sn=DC34677&sd=2022-11-14

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-pfizer-inc---pfe-301676371.html

SOURCE Pomerantz LLP

https://rt.newswire.ca/rt.gif?NewsItemId=DC34677&Transmission_Id=202211141435PR_NEWS_USPR_____DC34677&DateId=20221114

comtex tracking

COMTEX_418859979/1005/2022-11-14T14:35:08

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.